{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T23:58:02Z","timestamp":1648943882556},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologe"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00117-021-00948-7","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T18:21:00Z","timestamp":1639765260000},"page":"20-29","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positronen-Emissions-Tomographie\/Computertomographie (PET\/CT) beim multiplen Myelom"],"prefix":"10.1007","volume":"62","author":[{"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00259-016-3576-1","volume":"44","author":"EGM de Waal","year":"2017","unstructured":"de Waal\u00a0EGM, Glaudemans\u00a0AWJM, Schr\u00f6der\u00a0CP, Vellenga\u00a0E, Slart\u00a0RHJA (2017) Nuclear medicine imaging\u00a0of\u00a0multiple myeloma, particularly in the relapsed setting. Eur J Nucl Med Mol Imaging 44:332\u2013341. https:\/\/doi.org\/10.1007\/s00259-016-3576-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar\u00a0SV, Dimopoulos\u00a0MA, Palumbo\u00a0A et\u00a0al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"948_CR3","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo\u00a0M, Terpos\u00a0E, Nanni\u00a0C et al (2017) Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a\u00a0consensus statement by the international myeloma working group. Lancet Oncol 18:e206\u2013e217. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4","journal-title":"Lancet Oncol"},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni\u00a0E, Nanni\u00a0C, Patriarca\u00a0F et al (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50\u201355. https:\/\/doi.org\/10.3324\/haematol.10554","journal-title":"Haematologica"},{"key":"948_CR5","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","volume":"118","author":"D van Lammeren-Venema","year":"2012","unstructured":"van Lammeren-Venema\u00a0D, Regelink\u00a0JC, Riphagen\u00a0II, Zweegman\u00a0S, Hoekstra\u00a0OS, Zijlstra\u00a0JM (2012) 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a\u00a0systematic review. Cancer 118:1971\u20131981. https:\/\/doi.org\/10.1002\/cncr.26467","journal-title":"Cancer"},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","volume":"37","author":"YY Lu","year":"2012","unstructured":"Lu\u00a0YY, Chen\u00a0JH, Lin\u00a0WY et al (2012) FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a\u00a0systematic review and meta-analysis. Clin Nucl Med 37:833\u2013837. https:\/\/doi.org\/10.1097\/RLU.0b013e31825b2071","journal-title":"Clin Nucl Med"},{"key":"948_CR7","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau\u00a0P, Attal\u00a0M, Caillot\u00a0D et al (2017) Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Trial: results of the IMAJEM study. J\u00a0Clin Oncol 35:2911\u20132918. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975","journal-title":"J Clin Oncol"},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","volume":"48","author":"O Westerland","year":"2020","unstructured":"Westerland\u00a0O, Amlani\u00a0A, Kelly-Morland\u00a0C et al (2020) Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 48:2558\u20132565. https:\/\/doi.org\/10.1007\/s00259-020-05182-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel\u00a0TB, Haessler\u00a0J, Brown\u00a0TL et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068\u20132076. https:\/\/doi.org\/10.1182\/blood-2009-03-213280","journal-title":"Blood"},{"key":"948_CR10","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni\u00a0E, Patriarca\u00a0F, Nanni\u00a0C et al (2011) Prognostic relevance of 18\u2011F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118:5989\u20135995. https:\/\/doi.org\/10.1182\/blood-2011-06-361386","journal-title":"Blood"},{"key":"948_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","volume":"31","author":"S Han","year":"2021","unstructured":"Han\u00a0S, Woo\u00a0S, Kim\u00a0YI, Yoon\u00a0DH, Ryu\u00a0JS (2021) Prognostic value of\u00a018F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a\u00a0systematic review and meta-analysis. Eur Radiol 31:152\u2013162. https:\/\/doi.org\/10.1007\/s00330-020-07177-x","journal-title":"Eur Radiol"},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1038\/bcj.2015.87","volume":"5","author":"B Siontis","year":"2015","unstructured":"Siontis\u00a0B, Kumar\u00a0S, Dispenzieri\u00a0A et al (2015) Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer\u00a0J 5:e364","journal-title":"Blood Cancer J"},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni\u00a0E, Nanni\u00a0C, Gay\u00a0F et al (2016) 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30:417\u2013422. https:\/\/doi.org\/10.1038\/leu.2015.291","journal-title":"Leukemia"},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani\u00a0SZ, Mitchell\u00a0A, Waheed\u00a0S et al (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121:1819\u20131823. https:\/\/doi.org\/10.1182\/blood-2012-08-451690","journal-title":"Blood"},{"key":"948_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","volume":"103","author":"FE Davies","year":"2018","unstructured":"Davies\u00a0FE, Rosenthal\u00a0A, Rasche\u00a0L et al (2018) Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a\u00a0therapeutic goal in newly diagnosed multiple myeloma. Haematologica 103:1047\u20131053. https:\/\/doi.org\/10.3324\/haematol.2017.177139","journal-title":"Haematologica"},{"key":"948_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","volume":"21","author":"F Patriarca","year":"2015","unstructured":"Patriarca\u00a0F, Carobolante\u00a0F, Zamagni\u00a0E et al (2015) The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 21:1068\u20131073. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"948_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/diagnostics11040706","volume":"11","author":"K Yokoyama","year":"2021","unstructured":"Yokoyama\u00a0K, Tsuchiya\u00a0J, Tateishi\u00a0U (2021) Comparison of [18F]FDG PET\/CT and MRI for treatment response assessment in multiple myeloma: a meta-analysis. Diagnostics (Basel) 11:706. https:\/\/doi.org\/10.3390\/diagnostics11040706","journal-title":"Diagnostics (Basel)"},{"key":"948_CR18","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar\u00a0S, Paiva\u00a0B, Anderson\u00a0KC et\u00a0al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.3390\/jcm9113519","volume":"9","author":"E Zamagni","year":"2020","unstructured":"Zamagni\u00a0E, Tacchetti\u00a0P, Barbato\u00a0S, Cavo\u00a0M (2020) Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients. J\u00a0Clin Med 9:3519. https:\/\/doi.org\/10.3390\/jcm9113519","journal-title":"J Clin Med"},{"key":"948_CR20","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni\u00a0E, Nanni\u00a0C, Mancuso\u00a0K et\u00a0al (2015) PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 21:4384\u20134390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0396","journal-title":"Clin Cancer Res"},{"key":"948_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","volume":"33","author":"L Rasche","year":"2019","unstructured":"Rasche\u00a0L, Alapat\u00a0D, Kumar\u00a0M et\u00a0al (2019) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 33:1713\u20131722. https:\/\/doi.org\/10.1038\/s41375-018-0329-0","journal-title":"Leukemia"},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ajh.25507","volume":"94","author":"R Alonso","year":"2019","unstructured":"Alonso\u00a0R, Cedena\u00a0MT, G\u00f3mez-Grande\u00a0A et al (2019) Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol 94:853\u2013861. https:\/\/doi.org\/10.1002\/ajh.25507","journal-title":"Am J Hematol"},{"key":"948_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche\u00a0L, Angtuaco\u00a0E, McDonald\u00a0JE et al (2017) Low expression of hexokinase\u20112 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30\u201334. https:\/\/doi.org\/10.1182\/blood-2017-03-774422","journal-title":"Blood"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni\u00a0C, Zamagni\u00a0E, Versari\u00a0A et\u00a0al (2016) Image interpretation criteria for FDG PET\/CT in multiple myeloma: a\u00a0new proposal from an Italian expert panel. IMPeTus (Italian myeloma criteria for PET use). Eur J Nucl Med Mol Imaging 43:414\u2013421. https:\/\/doi.org\/10.1007\/s00259-015-3200-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"948_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s00117-013-2629-8","volume":"54","author":"A Dimitrakopoulou-Strauss","year":"2014","unstructured":"Dimitrakopoulou-Strauss\u00a0A (2014) PET-CT in der nuklearmedizinischen Diagnostik des multiplen Myeloms [PET-CT for nuclear medicine diagnostics of multiple myeloma. Radiologe 54:564\u2013566\u201371. https:\/\/doi.org\/10.1007\/s00117-013-2629-8","journal-title":"Radiologe"},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/molecules25010134","volume":"25","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis\u00a0C, Goldschmidt\u00a0H, Dimitrakopoulou-Strauss\u00a0A (2019) Positron emission tomography (PET) radiopharmaceuticals in multiple myeloma. Molecules 25:134. https:\/\/doi.org\/10.3390\/molecules25010134","journal-title":"Molecules"},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","volume":"83","author":"C Mesguich","year":"2014","unstructured":"Mesguich\u00a0C, Fardanesh\u00a0R, Tanenbaum\u00a0L, Chari\u00a0A, Jagannath\u00a0S, Kostakoglu\u00a0L (2014) State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings. Eur J Radiol 83:2203\u20132223. https:\/\/doi.org\/10.1016\/j.ejrad.2014.09.012","journal-title":"Eur J Radiol"},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","volume":"53","author":"R Fonti","year":"2012","unstructured":"Fonti\u00a0R, Larobina\u00a0M, Del Vecchio\u00a0S et al (2012) Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. J\u00a0Nucl Med 53:1829\u20131835. https:\/\/doi.org\/10.2967\/jnumed.112.106500","journal-title":"J Nucl Med"},{"key":"948_CR29","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","volume":"23","author":"JE McDonald","year":"2017","unstructured":"McDonald\u00a0JE, Kessler\u00a0MM, Gardner\u00a0MW et\u00a0al (2017) Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res 23:1981\u20131987. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0235","journal-title":"Clin Cancer Res"},{"key":"948_CR30","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.3324\/haematol.2018.213041","volume":"104","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis\u00a0C, Merz\u00a0M, Kopp-Schneider\u00a0A et al (2019) Quantitative dynamic\u00a018F-fluorodeoxyglucose positron emission tomography\/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. Haematologica 104:e420\u2013e423. https:\/\/doi.org\/10.3324\/haematol.2018.213041","journal-title":"Haematologica"},{"issue":"2","key":"948_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni\u00a0E, Nanni\u00a0C, Dozza\u00a0L et al (2021) Standardization of\u00a018F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J\u00a0Clin Oncol 39(2):116\u2013125. https:\/\/doi.org\/10.1200\/JCO.20.00386","journal-title":"J Clin Oncol"}],"container-title":["Der Radiologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-021-00948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-021-00948-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-021-00948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:09:29Z","timestamp":1642514969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-021-00948-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s00117-021-00948-7","relation":{},"ISSN":["0033-832X","1432-2102"],"issn-type":[{"value":"0033-832X","type":"print"},{"value":"1432-2102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"1 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Sachpekidis und A.\u00a0Dimitrakopoulou-Strauss geben an, dass kein Interessenkonflikt besteht. H.\u00a0Goldschmidt gibt folgende konkurrierende Interessen an: Grants and\/or provision of Investigational Medicinal Product: Amgen, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, John Hopkins University, Sanofi. Research Support (Institutions): Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma, Takeda, Novartis. Advisory Boards (Institutions): Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda. Honoraria (Speakers Bureaus): Amgen, ArtTempi, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Omnia Med Deutschland, Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle angewandten Verfahren stehen im Einklang mit den ethischen Normen der verantwortlichen Kommission f\u00fcr Forschung am Menschen (institutionell und national) und mit der Deklaration von Helsinki von 1975 in der revidierten Fassung von 2008. Alle Patienten wurden erst nach erfolgter Aufkl\u00e4rung und Einwilligung in die Studie eingeschlossen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}